EMPAVELI Sales Forecast

Key Factors Driving EMPAVELI Growth

Strong Clinical Differentiation Through C3 Complement Inhibition

EMPAVELI inhibits complement component C3, which sits upstream in the complement cascade. This allows the drug to block both intravascular and extravascular hemolysis, a limitation of earlier C5 inhibitors.

• Traditional therapies such as C5 inhibitors leave residual anemia and extravascular hemolysis, leading to incomplete response in many patients.
• Clinical trials showed pegcetacoplan improved hemoglobin levels and transfusion independence in PNH patients compared with C5 inhibitor therapy.

This differentiated mechanism has enabled EMPAVELI to capture a niche segment of patients inadequately controlled on C5 inhibitors, driving steady uptake in the rare disease market.

Expansion Beyond PNH Into Rare Kidney Diseases

A major catalyst for EMPAVELI growth is label expansion into nephrology indications.

• In July 2025, the FDA approved pegcetacoplan for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
• These diseases have very limited treatment options, creating strong demand for targeted complement inhibition.

Early launch metrics demonstrate strong uptake:

• 152 new patient start forms were recorded within the first two months after the nephrology launch.
• Market penetration in C3G/IC-MPGN reached over 5% early in the launch phase.

This expansion significantly increases the drug’s addressable market beyond PNH.

Continued Revenue Growth From PNH Market Adoption

EMPAVELI has maintained steady growth in its original PNH indication due to strong compliance and physician adoption.

• 97% patient compliance rates have been reported in real-world use.
• U.S. EMPAVELI revenue reached ~$98.1 million in 2024, up from about $91 million in 2023.
• Quarterly U.S. revenue was approximately $27 million in Q3 2025.

The drug benefits from a high-value orphan pricing model, typical in rare hematology diseases.

Pipeline Expansion Into Additional Complement-Mediated Diseases

Apellis is actively developing EMPAVELI across additional indications, which could substantially expand its revenue potential:

Upcoming programs include:

• Focal Segmental Glomerulosclerosis (FSGS) – planned Phase III trial
• Delayed Graft Function (DGF) in kidney transplantation
• HSCT-associated thrombotic microangiopathy

These indications represent large nephrology markets with significant unmet need, positioning pegcetacoplan as a potential broad complement inhibitor platform therapy.

Strategic Global Commercial Partnerships

Apellis partnered with Swedish Orphan Biovitrum (Sobi) for ex-U.S. commercialization.

• Apellis secured up to $300 million through a royalty purchase agreement related to ex-U.S. royalties for pegcetacoplan.

This partnership supports:

• Rapid global expansion
• Reduced commercialization costs
• Increased penetration in Europe and Japan.

EMPAVELI Recent Developments

• In December 2025, Apellis Pharmaceuticals announced that The New England Journal of Medicine (NEJM) published positive results from the Phase III VALIANT study investigating EMPAVELI (pegcetacoplan) for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.
• In October 2025, Apellis Pharmaceuticals announced new data from the open-label period of the Phase III VALIANT study that reinforce the robust and sustained efficacy of EMPAVELI (pegcetacoplan), a C3 inhibitor, in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), rare and debilitating kidney diseases. 

“EMPAVELI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of EMPAVELI for approved indication like Age-related macular degeneration, Membranoproliferative glomerulonephritis, and PNH; as well as potential indications like Glomerulonephritis, IgA nephropathy, Lupus nephritis, Membranous glomerulonephritis, and Thrombotic microangiopathy in the 7MM. A detailed picture of EMPAVELI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the EMPAVELI for approved and potential indications. The EMPAVELI market report provides insights about EMPAVELI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current EMPAVELI performance, future market assessments inclusive of the EMPAVELI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of EMPAVELI sales forecasts, along with factors driving its market.

EMPAVELI Drug Summary

EMPAVELI (pegcetacoplan) is a complement inhibitor injection developed by Apellis Pharmaceuticals for subcutaneous administration, primarily indicated for treating adults with paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by complement-mediated hemolysis, and more recently approved for adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) to reduce proteinuria. As the first FDA-approved PNH therapy targeting complement protein C3, it controls both intravascular and extravascular hemolysis by binding to C3, preventing immune-mediated destruction of red blood cells, thereby increasing hemoglobin levels, reducing transfusion needs, and stabilizing kidney function in C3G/IC-MPGN patients, with clinical data showing up to a 68% proteinuria reduction. Administered via infusion pump or injector, it carries a boxed warning for serious infections from encapsulated bacteria, requiring vaccination and REMS enrollment. The report provides EMPAVELI’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the EMPAVELI Market Report

The report provides insights into:

• A comprehensive product overview including the EMPAVELI MoA, description, dosage and administration, research and development activities in approved indications like Age-related macular degeneration, Membranoproliferative glomerulonephritis, and PNH; as well as potential indications like Glomerulonephritis, IgA nephropathy, Lupus nephritis, Membranous glomerulonephritis, and Thrombotic microangiopathy.
• Elaborated details on EMPAVELI regulatory milestones and other development activities have been provided in EMPAVELI market report.
• The report also highlights EMPAVELI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The EMPAVELI market report also covers the patents information, generic entry and impact on cost cut.
• The EMPAVELI market report contains current and forecasted EMPAVELI sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The EMPAVELI market report also features the SWOT analysis with analyst views for EMPAVELI in approved and potential indications.

Methodology

The EMPAVELI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EMPAVELI Analytical Perspective by DelveInsight

In-depth EMPAVELI Market Assessment

This EMPAVELI sales market forecast report provides a detailed market assessment of EMPAVELI for approved indication like Age-related macular degeneration, Membranoproliferative glomerulonephritis, and PNH; as well as potential indications like Glomerulonephritis, IgA nephropathy, Lupus nephritis, Membranous glomerulonephritis, and Thrombotic microangiopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted EMPAVELI sales data uptil 2034.

EMPAVELI Clinical Assessment

The EMPAVELI market report provides the clinical trials information of EMPAVELI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

EMPAVELI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

EMPAVELI Market Potential & Revenue Forecast

• Projected market size for the EMPAVELI and its key indications
• Estimated EMPAVELI sales potential (EMPAVELI peak sales forecasts)
• EMPAVELI Pricing strategies and reimbursement landscape

EMPAVELI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• EMPAVELI Market positioning compared to existing treatments
• EMPAVELI Strengths & weaknesses relative to competitors

EMPAVELI Regulatory & Commercial Milestones

• EMPAVELI Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

EMPAVELI Clinical Differentiation

• EMPAVELI Efficacy & safety advantages over existing drugs
• EMPAVELI Unique selling points
  

EMPAVELI Market Report Highlights

• In the coming years, the EMPAVELI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The EMPAVELI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EMPAVELI’s dominance.
• Other emerging products for Age-related macular degeneration, Membranoproliferative glomerulonephritis, and PNH; as well as potential indications like Glomerulonephritis, IgA nephropathy, Lupus nephritis, Membranous glomerulonephritis, and Thrombotic microangiopathy are expected to give tough market competition to EMPAVELI and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EMPAVELI in approved and potential indications.
• Analyse EMPAVELI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted EMPAVELI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of EMPAVELI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of EMPAVELI? How strong is EMPAVELI’s clinical and commercial performance?
• What is EMPAVELI’s clinical trial status in each individual indications such as Age-related macular degeneration, Membranoproliferative glomerulonephritis, and PNH; as well as potential indications like Glomerulonephritis, IgA nephropathy, Lupus nephritis, Membranous glomerulonephritis, and Thrombotic microangiopathy and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EMPAVELI Manufacturers?
• What are the key designations that have been granted to EMPAVELI for approved and potential indications? How are they going to impact EMPAVELI’s penetration in various geographies?
• What is the current and forecasted EMPAVELI market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of EMPAVELI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 
• What are the other emerging products available and how are these giving competition to EMPAVELI for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is EMPAVELI? What is the duration of therapy and what are the geographical variations in cost per patient?